secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2023-07-31T23:59:59+00:00
Accession:  0001558370-23-012506
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma signs exclusive deal with Medomie Pharma for ADHD drugs in Israel, Palestinian Authority
--------------------------------------------------------------------------------

- Exclusive collaboration, distribution and supply agreement for Adzenys XR-ODT and Cotempla XR-ODT in Israel and Palestinian Authority.
- Medomie will seek local regulatory approvals and marketing authorizations; first international commercial agreement for these ADHD products.
- Aytu CEO Josh Disbrow cites potential to improve patient compliance and reduce therapy misuse in underserved markets.
- No financial terms disclosed; export to Medomie after regulatory approvals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023012506/0001558370-23-012506-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000155837023012506/aytu-20230731x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-012506

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer